Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine oleh Joseph P. Casazza, Amelia R. Hofstetter, Pamela J. M. Costner, LaSonji A. Holman, Cynthia S. Hendel, Alicia T. Widge, Richard L. Wu, William R. Whalen, Jennifer Cunningham, Anita Arthur, Xiaolin Wang, Abidemi Ola, Jamie Saunders, Floreliz Mendoza, Laura Novik, Maria C. Burgos Florez, Ana M. Ortega-Villa, Preeti J. Apte, Larisa Strom, Lu Wang, Marjaan Imam, Manjula Basappa, Mursal Naisan, Mike Castro, Jessica F. Trost, Sandeep R. Narpala, Hillary A. Vanderven, Galina V. Yamshchikov, Nina M. Berkowitz, Ingelise J. Gordon, Sarah H. Plummer, Diane L. Wycuff, Sandra Vazquez, Rebecca A. Gillespie, Adrian Creanga, William C. Adams, Kevin Carlton, Jason G. Gall, Adrian B. McDermott, Leonid A. Serebryannyy, Katherine V. Houser, Richard A. Koup, Barney S. Graham, Julie E. Ledgerwood, John R. Mascola, Theodore C. Pierson, Sarah F. Andrews, Masaru Kanekiyo, Lesia K. Dropulic, The VRC 323 study team